Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

Pharmacopeia Elects to Expand Study to Include 1,000 mg Dose

PRINCETON, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that based on initial results from the Company's Phase 1 multiple ascending dose (MAD) study of its lead internal product candidate, PS433540 (DARA), no safety or tolerability issues were observed with any of the doses under evaluation. As a result, the study will be expanded to include a 1,000 mg dose. This study designed to evaluate 14 days of daily dosing in healthy volunteers, has already completed evaluation of 50, 100, 250 and 500 mg doses of PS433540. The Company expects to report findings from the 1,000 mg dose later this year.

"The purpose of a multiple ascending dose study of this nature is to determine the maximally tolerated dose of a compound in healthy volunteers. Since we did not reach that threshold with this study's original four doses, we've decided to expand the trial and evaluate this fifth dose level," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs. "The fact that this compound appears safe and well tolerated at a wide dose range will provide added dosing flexibility for subsequent clinical trials."

In addition, results from the initial Phase 1 trial of PS433540, a single ascending dose (SAD) study, indicated that the compound was well tolerated at all six doses administered, while also suggesting that PS433540 possesses a half-life that is consistent with once daily oral administration.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being dev
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...dy Expanded to 406 Subjects , , FRANKLIN, M...s Inc. (OTC Bulletin Board: PLCSF) announced today...Food and Drug Administration (FDA) for its U.S. pi...any,s RenalGuard System(TM) and associated therap...y (CIN). , , The FDA also approved PLC,s re...
(Date:11/25/2008)...TH SAN FRANCISCO, Calif., Nov. 25 ...velopment of novel therapeutics that target,prote...iseases, today,announced that data from two ongoi...iple myeloma will be presented at the upcoming 50t...ology (ASH). Carfilzomib is the first in a new cl...
(Date:11/25/2008)... VEGAS, Nov. 25 CardioVa... CVBT), announced today that it has,dosed the fir...ORD Phase II,clinical trial to treat patients wit...genesis for the treatment of CORonary heart Diseas...nd, placebo-controlled doses in approximately 120,...
(Date:11/24/2008)...ember is Pancreatic Cancer Awareness Month , ,...e/ -- The American Society for Gastrointestinal E...etwork are teaming up this November to raise aware...bout the disease and the resources that are availa...fourth leading cause of cancer deaths in the U.S. ...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6How America Signs Her Name 3B United Spinal Association Presents How to Display Our Flag 29302 1How America Signs Her Name 3B United Spinal Association Presents How to Display Our Flag 29302 2Genmab A S 3A Ofatumumab Pivotal CLL Data to be Presented at ASH 9055 1Genmab A S 3A Ofatumumab Pivotal CLL Data to be Presented at ASH 9055 2Genmab A S 3A Ofatumumab Pivotal CLL Data to be Presented at ASH 9055 3West Michigans Newest Medical Device Company Receives Support from the West Michigan Science 26 Technology Initiative and EDF Ventures 9054 1West Michigans Newest Medical Device Company Receives Support from the West Michigan Science 26 Technology Initiative and EDF Ventures 9054 2Meijer and Prescription Benefit Manager 4D Team Up to Create Innovative Prescription Insurance Program 29294 1Meijer and Prescription Benefit Manager 4D Team Up to Create Innovative Prescription Insurance Program 29294 2Meijer and Prescription Benefit Manager 4D Team Up to Create Innovative Prescription Insurance Program 29294 3
... market dynamics offers insights into,what will be...patients, NEW YORK, May 14, 2007 /PRNewswire-USNew...nt (TB Alliance), a not-for-profit,product develo...evelopment of new TB drugs, today released results...s of the global TB drug market,that offers a detai...
...ay 15, 2007 - Gemin X Biotechnologies,Inc. announc...ood,demonstrated that its lead compound, obatoclax... Cell Lymphoma (MCL) cell lines and,primary cells ...all,molecule specifically designed to inhibit all ...lidated cancer target, thus restoring,the natural ...
Other Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
(Date:12/1/2008)... Pa., Dec. 1 ViroPharma ...at the company submitted a supplemental,Biologics...rug Administration,(FDA) for Cinryze(TM) C1 Inhib...hereditary angioedema (HAE). , The sBLA is ...om a pivotal,Phase 3 acute treatment study of Cin...
(Date:12/1/2008)...l, nicotine use, personality illnesses common, stu...News) -- Psychiatric disorders are common among yo...tment, a new report shows. , To reach this find... 5,000 respondents, aged 19 to 25, who took part i... Related Conditions. , The study found that 45....
(Date:12/1/2008)...w analysis of the National Cancer Institute,s canc...older women experience delayed or incomplete radia..., and that this suboptimal care can lead to worse ...nell Medical College and colleagues found that amo...000 breast cancer registry patients aged 65 and ol...
(Date:12/1/2008)...GTON, Dec. 1 /PRNewswire-USNewswire/ -- American...e of a model state legislative resolution opposing...urges state legislatures to adopt the resolution i..., , Dr. Charmaine Yoest, AUL President &... endangers women,s health. It protects and promot...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...hat aging is just a state of mind. However, many d...cted by your hormone levels. Whether low or high, ...you age. // Speaking today at the American Academy...my, dermatologist Debra Jaliman, MD, FAAD, an assi...
... Administration's (FDA) approval of bottlers’ clai...by fluoridated water, is being backed by the Ameri...k fluoridated water from the tap or buy it in a bo...our oral health," says ADA executive director Jame...
...rug pain relief therapies suggests that hypnosis a...little research to assess how effective many compl...in labor," said lead study author Caroline Smith. ...d, she said, but "the results concerning acupunctu...
... pioglitazone (brand name Actos) has been linked t...e authors of a review which examined 22 studies of.... // Lead author Dr. Bernd Richter said ‘Our resu...udies of at least 24 weeks of pioglitazone treatme...
Other Medicine News:Health News:Hormones and the Skin: the Role Hormones Play as We Age 2Health News:Hormones and the Skin: the Role Hormones Play as We Age 3Health News:Hypnosis and Acupuncture Show Promise for Labor Pain 2Health News:Hypnosis and Acupuncture Show Promise for Labor Pain 3Health News:Diabetes Drug Benefits vs. Risks 2
...Med TruFlow™ Oxygen flowmeter with a Lexan&r...nty covering calibration and manufacturing defects...meet most needs. Also available with all popular i...f and double unit configurations. Our extra large ...
...ates to adults, the entire series of time-tested T...surpassed knowledge of the needs of care providers...y. You can see it in the craftsmanship. You can se...meter® Classic Flowmeter is hand-crafted and e...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value.
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value.
Medicine Products: